Prior Authorization/Medical Necessity Letter (Advanced Wound Therapies)

(Use short, objective paragraphs with specific measurements and dates. If any criterion-linked element such as perfusion status, infection status, or offloading/compression is not available, explicitly document as pending, contraindicated, or declined with dates and plan. Do not leave criterion-linked elements blank.)

From: [Ordering clinician full name], [Credentials], [Specialty/Role], [Practice or Facility Name], [Address], [Phone], [Fax], [NPI]

Date: [Full date]

To: [Payer name], [Utilization Management Department], [Fax number if known]

Patient: [Full name], [Date of birth], [Member ID], [Claim or authorization reference number if assigned]

Re: Prior Authorization Request — [Therapy requested] for [Wound type and location with laterality]

Request Summary

[Therapy requested] in [home / clinic / outpatient facility] setting starting [Requested start date] for [Anticipated duration or number of sessions].

[Primary wound diagnosis] — [Etiology], [Anatomic location], [Laterality], [Severity classification with system named].

[Why now rationale] (2–3 sentences summarizing chronicity with initial date, objective non-healing trajectory despite standard care with dates, and specific wound features necessitating the advanced modality.)

Enclosures: [One-line list of attachments, e.g., wound measurement trend table, visit notes, vascular studies, photos, debridement notes, labs].

Clinical Context

(Include only factors that materially affect wound healing or therapy risk. Mark unavailable items as pending with expected date, or omit if not applicable.)

• [Diabetes status: A1c value and date / No diabetes]
• [Peripheral arterial disease: ABI, TBI, or TcPO2 with dates; duplex or CTA findings if available; revascularization status]
• [Venous disease: reflux or duplex findings with dates / Not present]
• [Neuropathy: present or absent with testing or exam findings]
• [Tobacco exposure: current, former, or never; pack-years if applicable]
• [Nutrition status: BMI, weight change over timeframe; albumin or prealbumin with dates if obtained]
• [Renal disease: eGFR with date; dialysis schedule if applicable]
• [Immunosuppression or chronic steroids: agent and dose with dates / None]
• [Mobility and pressure risk: limitations, support surface, repositioning schedule]
• [Medications impacting therapy: anticoagulants, immunosuppressants; recent antibiotics for wound infection with date ranges]
• [Adherence considerations: offloading or compression compliance, caregiver support, barriers to care]

Index Wound Characterization

Wound #1: [Anatomic location and laterality]

• [Date first noted] and [Precipitating event if any]
• [Etiology and classification] (State the classification system explicitly, e.g., Wagner grade for DFU, pressure injury stage, CEAP for venous disease.)
• [Complicating factors: infection status with culture dates and results; osteomyelitis evaluation with imaging or biopsy if performed; perfusion status with testing and dates; exposed structures; tunneling or undermining with measurements]

(Repeat for additional qualifying wounds as needed.)

Wound Assessment and Measurement Trajectory

Most recent assessment ([Date]): Dimensions [L × W × D cm]; Area [cm²]; Drainage [amount and type]; Tissue composition [granulation %, slough %, eschar %]; Edges [description]; Periwound [condition].

Measurement trend table: (Include baseline at start of standard care and serial measurements at clinically meaningful intervals, weekly preferred.)

Date	Dimensions (L × W × D cm)	Area (cm²)	% Change from Baseline
[Baseline date]	[L × W × D]	[Area]	0%
[Date]	[L × W × D]	[Area]	[% change]
[Date]	[L × W × D]	[Area]	[% change]

Interpretation: [Total duration of standard care with date range], [Cumulative percent area change], [Statement explaining why trajectory demonstrates stalled or non-healing wound].

(If serial measurements are limited, explain why and state plan to obtain ongoing measurements. Reference enclosed photographs with dates.)

Standard Wound Therapies Attempted

• Local wound care: [Cleansing protocol]; [Dressing types and change frequency]; [Moisture balance strategy]; [Debridement type and dates].
• Infection management: [Clinical assessments]; [Culture dates and results]; [Antibiotic courses with drug names and date ranges].
• Vascular management: [Assessment performed with results]; [Revascularization interventions with dates / Rationale if deferred or contraindicated].
• Etiology-specific mechanical therapy: [Offloading method and adherence for DFU / Compression type and adherence for VLU / Repositioning schedule and support surface for pressure injury].
• Systemic optimization: [Glycemic control measures]; [Nutrition evaluation]; [Smoking cessation counseling]; [Edema management].

Therapy timeline:

Therapy	Start Date	End Date / Ongoing	Objective Response
[Therapy name]	[Date]	[Date / ongoing]	[Measurement-based change]
[Therapy name]	[Date]	[Date / ongoing]	[Measurement-based change]

Summary: Standard care has been insufficient as evidenced by [objective findings: limited area reduction, persistent drainage, stalled granulation, ongoing depth or undermining]. (If any standard component was not performed, document why: contraindicated, not clinically appropriate, or patient declined.)

Advanced Therapy Requested

Negative Pressure Wound Therapy

(Include only if requesting NPWT.)

Clinical indication: [Qualifying wound features: depth, undermining, exudate burden, post-surgical status, graft or flap support].

Rationale for NPWT: [Relate wound characteristics and lack of response to standard care].

Proposed plan: [Device or system]; [Dressing change frequency]; [Who performs changes]; [Care setting]; [Monitoring plan including measurement and photo cadence].

Continuation criteria: [Objective thresholds, e.g., target percent area reduction or granulation improvement by timeframe].

Stop rules: [Plateau over specified weeks, adequate granulation for closure, adverse events].

Hyperbaric Oxygen Therapy

(Include only if requesting HBOT.)

Covered indication: [Indication category] with [Wound severity classification and system named].

Standard therapy confirmation: [Duration and components delivered with dates] with [Documentation of no measurable healing].

Proposed course: [Number of sessions]; [Frequency]; [Start date and timeframe].

Reassessment plan: Reassess at least every 30 days with [Objective healing markers required to continue]. Treatment will be discontinued if measurable healing is not demonstrated within any 30-day period.

Cellular and/or Tissue-Based Product

(Include only if requesting CTP or skin substitute.)

Ulcer qualification: [Ulcer type], [Chronicity], [Non-healing status with percent area reduction over 4 weeks if available; note failure to achieve approximately 50% reduction by 4 weeks if applicable].

Wound bed preparation: [Debridement status with dates]; [Infection control status]; [Bioburden management].

Perfusion status: [Adequate perfusion documented with test results and dates / Assessment pending with expected date].

CTP plan: [Product name if payer-specific]; [Application frequency]; [Anticipated number of applications]. Concomitant therapy will be maintained: [offloading for DFU / compression for VLU].

Other Advanced Modality

(Include only if requesting other therapy not listed above.)

[Modality name and role as adjunct]; [Specific indication]; [Proposed course]; [Objective goals]; [Why standard therapy alone is insufficient].

Medical Necessity Rationale

Problem statement: This patient has [specific wound type] that remains non-healing after [duration] of standard wound therapy with documented adherence.

Risks if not approved: [Patient-specific risks: progression of infection, hospitalization, limb loss, delayed surgical closure].

Why therapy is reasonable and necessary:

• [Wound characteristics that indicate need for requested therapy]
• [Standard care attempted and objective non-response]
• [Therapy mechanism aligned with wound needs, e.g., exudate control, perfusion-dependent healing, scaffold for closure]
• [Patient-level risk modifiers and mitigation plan]

Measurable treatment goals: [Target percent area reduction by timeframe]; [Depth reduction by timeframe]; [Granulation increase to target]; [Readiness for closure by timeframe].

Payer criteria crosswalk: (Include if payer policy has explicit criteria.)

• [Criterion] — Documented in: [Section]; Supported by: [Enclosure with date]
• [Criterion] — Documented in: [Section]; Supported by: [Enclosure with date]

Safety and Contraindications

[Modality-specific contraindications assessed: none identified / Specific concerns identified and addressed with rationale].

[Adverse event mitigation plan if relevant: monitoring schedule, management considerations, when to pause or stop therapy].

Follow-Up Plan

[Reassessment provider] will reassess at [frequency] with measurements and photos at [interval] and debridement as indicated.

Discontinuation or change criteria: [Objective criteria for discontinuation or therapy modification if goals are not met by specified timeframes].

Enclosures

• [Wound measurement flowsheet with dates]
• [Wound photographs with dates]
• [Clinic visit notes with dates]
• [Debridement or procedure notes with dates]
• [Vascular studies with dates]
• [Relevant labs with dates]
• [Culture and antibiotic records with dates]
• [Offloading or compression documentation with dates]
• [Pending studies with expected completion dates]

Closing

Please approve prior authorization for [Therapy requested] for [Wound type and location with laterality]. Peer-to-peer discussion is welcomed if additional information would be helpful.

Contact: [Direct phone], [Fax], [Secure email if available], [Preferred callback availability]

Signature: [Clinician signature], [Printed name], [Credentials], NPI: [NPI], Date: [Date]